SEC’s Warning To Biopharma: Report FDA Dialogue Accurately
This article was originally published in RPM Report
Executive Summary
The Securities & Exchange Commission’s top enforcement official urges biopharma companies to disclose FDA correspondence as the best step to avoid potential compliance issues with the investor watchdog agency. Here is an excerpt from his remarks to the CBI Pharmaceutical Compliance Congress on March 3.